Nu Skin Enter SEC Filings

Nu Skin Enterprises director reports small share increase through plan dividend

A Nu Skin Enterprises, Inc. director filed a Form 4 reporting the acquisition of 10 shares of Class A common stock on 12/10/2025 at a price of $10.35 per share. The filing states these shares were acquired through dividend reinvestment under the company’s Deferred Compensation Plan in accordance with the plan’s terms. Following this transaction, the director beneficially owns 42,979 shares, held directly. This is a routine insider ownership update showing plan-based reinvestment rather than an open-market trade.

Nu Skin Enterprises (NUS) insider transaction: Chief Product Officer Steven Hatchett reported buying 5,500 shares of Class A Common Stock on 11/11/2025 at $9.61 per share, according to a Form 4 filing.

Following the purchase, Hatchett beneficially owns 167,565 shares, held directly. The filing was signed by attorney-in-fact Gregory Belliston on 11/12/2025.

Nu Skin Enterprises (NUS) reported Q3 2025 results. Revenue was $364.2 million, down 15% year over year as macro headwinds weighed on demand and field activity. Operating income rose to $21.6 million from $18.2 million. Net income was $17.1 million ($0.34 diluted EPS) versus $8.3 million a year ago.

For the first nine months of 2025, revenue was $1,114.8 million, down 13% year over year. Net income reached $145.7 million, reflecting a $176.2 million gain on the January sale of the Mavely business. Core costs were lower: selling and G&A declined versus last year, and restructuring charges were significantly lower than 2024.

The balance sheet strengthened. Cash and cash equivalents were $251.8 million versus $186.9 million at year-end 2024. Long-term debt fell to $209.0 million from $363.6 million, aided by $220.0 million of debt payments year-to-date, including a $115.0 million term-loan paydown funded by sale proceeds. The company paid quarterly dividends of $0.06 per share and repurchased $10.0 million of stock year to date, with $152.4 million remaining under the authorization. As of November 1, 2025, 48,750,076 Class A shares were outstanding.

Nu Skin Enterprises (NUS) furnished an 8‑K announcing it issued a press release with financial results for the three‑ and nine‑month periods ended September 30, 2025. The release is included as Exhibit 99.1 and the information under Item 2.02 is furnished, not filed, under the Exchange Act. The report lists Class A Common Stock trading on the NYSE and is signed by CFO James D. Thomas.

Edwina D. Woodbury, a director of Nu Skin Enterprises, Inc. (NUS), reported an acquisition of Class A common stock on 09/10/2025. The filing shows shares were acquired at a price of $11.52 under the company’s Deferred Compensation Plan via dividend reinvestment. Following the transaction, Ms. Woodbury beneficially owns 42,969 shares. The Form 4 was signed by an attorney-in-fact on 09/11/2025. The filing lists the transaction as a direct ownership change and notes the dividend reinvestment as the reason for the share increase.

Laura Nathanson, a director of Nu Skin Enterprises (NUS), reported a sale of 6,489 shares of Class A common stock on 09/04/2025 at a price of $12.22 per share. After the transaction she beneficially owns 33,149 shares, reported as directly held. The Form 4 was signed by an attorney-in-fact on her behalf.

Nu Skin Enterprises insider sale summary. EVP and General Counsel Chayce Clark reported a sale of 20,000 shares of Class A common stock on 09/03/2025 at a weighted-average price of $11.97 per share. After the reported disposition, the reporting person beneficially owned 233,140 shares, held directly. The Form 4 shows no derivative transactions and was signed by an attorney-in-fact on behalf of the reporting person on 09/04/2025. The filing includes an explanation that the reported price is a weighted average from multiple trades between $11.96 and $12.01.

NuSkin Enterprises, Inc. (NUS) Form 144 shows a proposed sale of 6,489 Class A shares through William Blair in Chicago, to be executed approximately on 09/04/2025 on the NYSE. The filing lists an aggregate market value of $77,868.00 and reports 49,497,715 Class A shares outstanding for the issuer.

The 6,489 shares were acquired from the issuer as compensation across annual grant dates: 04/30/2021 (422 shares), 04/30/2022 (2,467), 04/30/2023 (3,179) and 04/30/2024 (421), with matching payment dates. The filer reports no securities sold in the past three months and includes the standard attestation regarding absence of undisclosed material adverse information.

Nu Skin Enterprises (NUS) filing a Form 144 notifies the SEC of a proposed sale of 20,000 Class A shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $239,433.56 and approximately 49,497,715 Class A shares outstanding. The securities listed were acquired as restricted stock vesting from the issuer on multiple dates between 02/15/2022 and 02/15/2024, with individual lot sizes shown. The filer reports no securities sold in the past three months and affirms they possess no undisclosed material adverse information about the issuer. The notice includes required signature and legal attestation language.